Background And Aims: Severe preeclampsia increases lifetime-risk for cardiovascular disease (CVD). It remains unclear when this risk translates to subclinical atherosclerosis and whether this is related to cardiovascular health (CVH) after pregnancy. Our aims were (1) to determine CVH after severe preeclampsia, (2) to relate CVH to carotid intima-media thickness (CIMT), as a marker of subclinical atherosclerosis and (3) to relate CVH to chronological and vascular age.

Methods: A prospective cohort study was performed in women with previous severe pre-eclampsia. CVH, proposed by the American Heart Association, was assessed one year after pregnancy. The CVH score (range 0-14) includes seven metrics (blood pressure, total-cholesterol, glucose, smoking, physical activity, diet and body mass index [BMI]), each weighted as poor (0), intermediate (1) or ideal (2). Vascular age was determined by CIMT. We related CVH to delta age (chronological age - vascular age).

Results: In 244 women, the median CVH score was 10 (90% range 7.0, 13.0). Low CVH (<10) was associated with a larger CIMT than high CVH (≥12) (median 626.3 μm vs. 567.0 μm, respectively). Higher CVH was also associated with a lower vascular age (-2.0 years, 95%CI -3.3, -0.60). Women with low CVH had a larger delta age (22.5 years [90% range -3.9, 49.6) than women with high CVH (16.5 years [90% range -11.9, 43.3).

Conclusions: CVH is inversely related to subclinical atherosclerosis and to vascular age one year after severe preeclampsia. Especially low CVH is associated with a large difference between chronological age and vascular age. CVH counseling might provide the opportunity for timely cardiovascular prevention.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2019.11.023DOI Listing

Publication Analysis

Top Keywords

severe preeclampsia
12
cvh
9
cardiovascular health
8
vascular age
8
cohort study
8
subclinical atherosclerosis
8
relate cvh
8
cvh score
8
vascular
4
health vascular
4

Similar Publications

This systematic review aimed to explore the efficacy of both pharmacological and non-pharmacological interventions in managing hypertension during pregnancy. It analyzed high-quality randomized controlled trials (RCTs), focusing on outcomes related to maternal and fetal health. The findings demonstrated that antihypertensive medications, particularly labetalol and nifedipine, effectively reduced the risks of severe preeclampsia (PE), preterm birth, and other complications.

View Article and Find Full Text PDF

Hyperemesis gravidarum (HG) is a severe condition marked by intense nausea and vomiting during pregnancy, which is different from typical morning sickness. It is marked by weight loss exceeding 5% of pre-pregnancy weight, ketonuria, dehydration, electrolyte imbalances, and in some cases, arrhythmias - primarily linked to electrolyte disturbances. Treatment typically involves conservative measures such as small, bland meals, medications like metoclopramide and ondansetron, and correction of electrolyte abnormalities.

View Article and Find Full Text PDF

Background: Pregnant patients with cardiovascular disease (CVD) face increased risk of preeclampsia and preterm delivery, yet data is limited data regarding degree of risk and impact of hypertensive disorders of pregnancy (HDP) on gestational age at delivery.

Objectives: To examine HDP risk and impact on delivery timing in patients with CVD.

Methods: This retrospective cohort study included patients >18 years old who delivered between 10/1/2015 and 12/31/2020 using the Premier Healthcare Database.

View Article and Find Full Text PDF

Background: Given the distinctive physiological characteristics of pregnant women, non-pharmacological therapies are increasingly being used to improve depressive and anxiety symptoms. Our objective was to explore and compare the impact of various non-pharmacological interventions in improving depressive and anxiety symptoms, and to identify the most effective strategies for pregnant women with depressive and/or anxiety symptoms.

Methods: We conducted a systematic search of PubMed, Embase, the Cochrane Library, and Web of Science for randomized controlled trials (RCTs) that compared non-pharmacological interventions to usual care, from the inception of each database up to October 5, 2024.

View Article and Find Full Text PDF

Background: Evidence suggests L-arginine may be effective at reducing pre-eclampsia and related outcomes. However, whether L-arginine can prevent or only treat pre-eclampsia, and thus the target population and timing of initiation, remains unknown.

Objectives: To evaluate the effects of L-arginine and L-citrulline (precursor of L-arginine) on the prevention and treatment of pre-eclampsia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!